The entire staff at the Multiple Sclerosis Association of America (MSAA), as well as many of MSAA’s corporate partners, are mourning the loss of our former Chief Operating Officer and treasured colleague, Robert “Bob” Rapp. Following a successful career in education and public service, Bob joined the staff of MSAA as Director of Services in […]

EMD Serono, Inc. announced today that the United States Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Cladribine Tablets (an oral formulation of cladribine), an investigational treatment for relapsing forms of MS. Accepted by the European Commission in August 2017 and by Canada in December 2017, Cladribine is currently approved […]

In this Article Disease-Modifying Therapies in the Research Pipeline Long-Term Efficacy and Safety of Approved DMTs Comparative Analyses of Approved DMTs New Diagnostic Testing Various Strategies for Wellness and Symptom Management, Physical Activity and Exercise, Vitamin D, and Reproductive-Health Topics Hot Topics in MS: Stem Cells, Lipoic Acid, Diet and MS, Obesity and MS, Gut […]

My MS Manager™ is the Multiple Sclerosis Association of America’s mobile phone app designed to be a convenient and effective tool for members of the MS community to help manage their condition. The app, powered by @Point of Care, is available to download free of charge for both iOS and Android devices. Features available in […]

The MRI Access Fund assists with the payment of cranial (brain) and c-spine MRI scans for qualified individuals who have no medical insurance or cannot afford their insurance costs. The exam must be required by a physician to help determine a diagnosis of multiple sclerosis or evaluate current MS disease progression.

On May 11, 2018, Novartis announced that Gilenya® (fingolimod) was approved by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents, ages 10 through 17, with relapsing multiple sclerosis (MS). This is the first disease-modifying therapy (DMT) to be approved for this form of the disease in this age […]

As a follow-up to MSAA’s online article, “Zinbryta® Withdrawn from Marketplace,” MSAA is alerting individuals taking Zinbryta® (daclizumab) to additional information on the withdrawal. On March 14, 2018, the United States Food and Drug Administration (FDA) issued a press release to assist with the withdrawal of Zinbryta from the market in the United States. They […]